Chemical Component Summary

Name2'-DEOXYCOFORMYCIN
Identifiers(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-6H-imidazo[4,5-f][1,3]diazepin-8-ol
FormulaC11 H16 N4 O4
Molecular Weight268.27
TypeNON-POLYMER
Isomeric SMILESc1nc2c(n1[C@H]3C[C@@H]([C@H](O3)CO)O)N=CNC[C@H]2O
InChIInChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
InChIKeyFPVKHBSQESCIEP-JQCXWYLXSA-N

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count4
Bond Count37
Aromatic Bond Count5

Drug Info: DrugBank

DrugBank IDDB00552 
NamePentostatin
Groups
  • approved
  • investigational
DescriptionA potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Synonyms
  • Pentostatin
  • Pentostatina
  • Pentostatinum
  • Co-vidarabine
  • Pentostatine
Brand Names
  • Nipent Pws 10mg/vial
  • Nipent
  • Pentostatin
IndicationFor the treatment of hairy cell leukaemia refractory to alpha interferon.
Categories
  • Adenosine Deaminase Inhibitors
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Carbohydrates
  • Cardiotoxic antineoplastic agents
ATC-CodeL01XX08
CAS number53910-25-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Adenosine deaminaseMAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVI...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDDFIMZP01
PubChem439693
ChEMBLCHEMBL1580
PharosCHEMBL1580